Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Finco

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Dermatologica|January 1, 1990
Can C4AQO decreased frequency be considered a genetic marker for vitiligo and familial melanoma?G Orecchia, L Perfetti, M Cuccia, et al.
Complement and Inflammation|January 1, 1991
HLA complement markers in Italian narcoleptic patients with special emphasis on BfF subtypingM Cuccia, O Finco, R Conte, et al.
Dermatology (Basel, Switzerland)|January 1, 1992
Polymorphisms of HLA class III genes in allergic contact dermatitisG Orecchia, L Perfetti, O Finco, et al.
Clinical Genetics|January 1, 1991
Age of onset in vitiligo: relationship with HLA supratypesO Finco, M Cuccia, M Martinetti, et al.
AIDS (London, England)|December 22, 1999
Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic miceS Toneatto, O Finco, H van der Putten, et al.
The Journal of Experimental Medicine|February 1, 1992
Structural differences between the two human complement C4 isotypes affect the humoral immune responseO Finco, S Li, M Cuccia, et al.
Complement and Inflammation|January 1, 1991
Sarcoidosis and major histocompatibility complex genes with special emphasis on BF F subtypesO Finco, M Martinetti, E Dondi, et al.
Annals of the New York Academy of Sciences|March 22, 1996
Neutral endopeptidase modulates septic shockB Lu, N P Gerard, L F Kolakowski, et al.
European Journal of Immunology|May 16, 1998
Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmidR Grifantini, O Finco, E Bartolini, et al.
Sarcoidosis|September 1, 1991
HLA markers in sarcoidosisM Luisetti, M Martinetti, M Cuccia, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Dermatologica|January 1, 1990
Can C4AQO decreased frequency be considered a genetic marker for vitiligo and familial melanoma?G Orecchia, L Perfetti, M Cuccia, et al.
Complement and Inflammation|January 1, 1991
HLA complement markers in Italian narcoleptic patients with special emphasis on BfF subtypingM Cuccia, O Finco, R Conte, et al.
Dermatology (Basel, Switzerland)|January 1, 1992
Polymorphisms of HLA class III genes in allergic contact dermatitisG Orecchia, L Perfetti, O Finco, et al.
Clinical Genetics|January 1, 1991
Age of onset in vitiligo: relationship with HLA supratypesO Finco, M Cuccia, M Martinetti, et al.
AIDS (London, England)|December 22, 1999
Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic miceS Toneatto, O Finco, H van der Putten, et al.
The Journal of Experimental Medicine|February 1, 1992
Structural differences between the two human complement C4 isotypes affect the humoral immune responseO Finco, S Li, M Cuccia, et al.
Complement and Inflammation|January 1, 1991
Sarcoidosis and major histocompatibility complex genes with special emphasis on BF F subtypesO Finco, M Martinetti, E Dondi, et al.
Annals of the New York Academy of Sciences|March 22, 1996
Neutral endopeptidase modulates septic shockB Lu, N P Gerard, L F Kolakowski, et al.
European Journal of Immunology|May 16, 1998
Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmidR Grifantini, O Finco, E Bartolini, et al.
Sarcoidosis|September 1, 1991
HLA markers in sarcoidosisM Luisetti, M Martinetti, M Cuccia, et al.
Pageof 2